International Journal of Clinical Pharmacology and Therapeutics · 2018 · 10 citations · 0 references
PharmacyPharmacologyPharmacotherapyCancer PharmacologyHypersensitivityOncology PharmacotherapyDrug AllergyDrug-induced Skin ReactionsLung Cancer PharmacotherapySkin IrritationToxicity Risk AssessmentTyrosine Kinase InhibitorsAdverse Event DetectionDrug-induced Skin HypersensitivityEgfr InhibitionEpidermal Growth Factor Receptor InhibitionNon-small Cell Lung Cancer TherapyNon-small Cell Lung Cancer TreatmentNonsteroidal Anti-inflammatory Drug ToxicityPrevention Of Skin Toxicity
OBJECTIVES: Skin rash is a common adverse event induced by epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI). Here, we aimed to predict factors that reduce EGFR-TKI-related skin rash. MATERIALS AND METHODS: We conducted a single-center, retrospective study to predict factors that reduce skin rash in patients undergoing treatment for non-small cell lung cancer (NSCLC) with EGFR-TKIs using Cox proportional hazards model. RESULTS: Cox proportional hazard analysis revealed that coadministration of non-steroidal anti-inflammatory drug (NSAID) had protective effects against rash. Steroid coadministration showed a trend to being effective in reducing rash. CONCLUSION: NSAIDs may be useful in preventing EGFR-TKI-related skin rash. .